Pharma

pause button on blue background
Biotech

UniQure halts mid- to high-dosing for AAV gene therapy

Two patients receiving uniQure’s gene therapy at a mid-level dose have experienced asymptomatic Grade 3 liver enzyme elevations.
An arrow incrementally going up stairs before pointing straight up Blue background

Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease

Feb 5, 2026 12:15pm
Astellas
Favicon Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am
Multiple screens displaying stock tickers and financial information

GE HealthCare posts higher revenues amid turbulent tariffs

Feb 5, 2026 10:45am
Hundred dollar bills flowing out of faucet

Angitia raises $130M to advance bone-building bispecifics

Feb 5, 2026 10:17am
new york stock exchange
Favicon Fierce Pharma

Veradermics locks in $256M IPO, shares spike

Feb 5, 2026 10:01am